

# ASX Release

---

## SUDA ENTERS FEASIBILITY AGREEMENT WITH PFIZER

**PERTH, AUSTRALIA – 29 March 2017:** SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that it has entered into a feasibility agreement with Pfizer Consumer Healthcare.

Under the agreed work plan, SUDA will apply its proprietary OroMist® oro-mucosal spray technology to two over-the-counter (OTC) molecules for evaluation by Pfizer.

Mr Stephen Carter, SUDA's CEO and Managing Director, commented: "We are delighted to be working with Pfizer to assess the feasibility of two interesting drugs with our OroMist® platform, where we believe that our technology can offer a unique advantage."



**Further information:**

**STEPHEN CARTER**

**CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR**

**SUDA LTD**

Tel: +61 8 6142 5555

[sjcarter@sudaltd.com.au](mailto:sjcarter@sudaltd.com.au)

**NOTES TO EDITORS:**

**About SUDA LTD**

SUDA LTD (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes Zolpimist™, a first-in-class oral spray of zolpidem for insomnia. Zolpimist™ is marketed in the USA and SUDA has rights to the product outside of North America. SUDA's most advanced development-stage product, ArTiMist®, is a novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist® was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction and pre-procedural anxiety. For more information, visit [www.sudaltd.com.au](http://www.sudaltd.com.au)